Some Republican senators are mobilizing against the White House rescissions package and its $900 million in global health cuts — enough to put its Senate passage in jeopardy.

Why it matters: The fate of some funding for PEPFAR, maternal health programs and other aid hinges on whether Congress passes the package by July 18.

What they're saying: Sen. Lisa Murkowski said yesterday that she couldn't support the package in its current form.

• Sen. Susan Collins has been reiterating her concerns with PEPFAR and public broadcasting cuts, using an interview last night with the Christian Broadcasting Network to criticize "the hundreds of millions of dollars that the OMB has proposed" taking back.
• Majority Leader John Thune told reporters yesterday that the amendment process would be "fairly open" and that proposed changes would "probably get votes."
• Other senators including Mike Rounds and Jerry Moran have expressed concern with public broadcasting cuts affecting stations in outlying areas.

Catch up quick: The $9.4 billion package that OMB sent to the Hill includes DOGE-directed cuts to State Department and USAID global health programs.

• It calls for eliminating $500 million for USAID programs addressing child and maternal health and infectious diseases, and $400 million for HIV/AIDS prevention, which includes PEPFAR.

Between the lines: Any amendments offered to the package have to be germane to the bill, and further cuts cannot be added. These amendments will be offered on the Senate floor, rather than in the Appropriations Committee.

• That "germaneness" requirement narrows the number and type of amendments that can be offered, particularly by Democrats. Despite that, senators are prepared for another vote-a-rama.
• Any changes would also have to clear the House.

What's next: Thune told Axios' Stef Kight this week that rescissions would be "a next-week exercise" and that there would probably be a motion to discharge the package from the Appropriations Committee to the Senate floor.

• Only seven legislative days remain until the July 18 deadline.

Senate appropriators today unanimously approved an FY26 Agriculture-FDA spending bill, 27–0, after debating amendments on hemp and the Agricultural Research Service.

Why it matters: The bill maintains FDA funding at essentially FY25 levels, like the House version, insulating the agency from major cuts.

• Congress appears headed toward another continuing resolution to keep the government funded past Sept. 30.

What's inside: The Senate Appropriations Committee customarily approves spending bills before revealing the full text, so final numbers weren't immediately available.

• Full text will be posted on the committee's webpage sometime today.
• Appropriations Ranking Member Patty Murray said the bill has targeted increases for food safety, WIC and other agriculture-related programs.
• Ag-FDA subcommittee Chair John Hoeven said the funding level for the bill was at 1% above the enacted FY25 continuing resolution.
• Hoeven said the 302(b) allocation of $21.7 billion was "the exact same number" that Senate appropriators allocated last year. He also said that the FDA and the Food Safety Inspection Service were fully funded.

State of play: Ag-FDA was among the first and least controversial of the appropriations bills that senators marked up, with battles ahead for Labor-HHS, Commerce-Justice-State and other titles.

• The House has passed only the Milcon-VA bill. Its Appropriations Committee advanced a handful of bills including Ag-FDA on party line votes.
• The House would fund the FDA at a relatively flat $6.79 billion, which is in line with President Trump's budget request.

1. Benefit conditions: HHS announced a policy shift that will impose citizenship requirements on public benefits like Head Start, mental health and substance abuse treatment and federally funded health centers.
2. Visa support: Health employers, especially those seeking physicians and surgeons, are increasingly offering immigrants help in obtaining visas and green cards, Emily Peck reports.
3. COVID shots: Moderna said the FDA approved its COVID-19 vaccine for children 6 months through 11 years old who are at increased risk of the disease.